Well-Differentiated Papillary Mesothelioma Complete Response after Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (LHIPEC) Plus Intraperitoneal Chemotherapy; And a Review of the Literature

Ching-Hsien Ling¹; Haruaki Ishibashi²; Takuji Fujita³; Yang Liu¹; Satoshi Wakama³; Syouzou Sako³; Toshiyuki Kita³; Yasuo Hirono⁴; Keizou Taniguchi⁵; Daisuke Fujimoto⁶; Yen-Cheng Chen¹; Yutaka Yonemura²,3,4*

¹Department of Surgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
²Asian School of Peritoneal Surface Malignancy Treatment, Kyoto City, Kyoto Prefecture, Japan, 600-8189.
³Department of Regional Cancer Therapy, Peritoneal Dissemination Center, Kishiwada Tokushukai Hospital, Kishiwada City, Osaka Prefecture, Japan, 596-8522.
⁴Department of Regional Cancer Therapy, Peritoneal Dissemination Center, Kusatsu General Hospital, Japan.
⁵Department of Surgery, Mizonokuchi Hospital, Teikyo University, School of medicine, Kawasaki, Kanagawa, 213-8507, Japan.
⁶School of Medicine, Tzu Chi University, Hualien, Taiwan.

*Corresponding Author(s): Yutaka Yonemura
Representative of Asian School of Peritoneal Surface Malignancy Treatment. Department of Regional Cancer Therapies, Peritoneal Surface Malignancy Treatment Center, Kishiwada Tokushukai Hospital, Osaka, Japan.
Email: yyonemura@coda.ocn.ne.jp

Received: Aug 10, 2023
Accepted: Aug 29, 2023
Published Online: Aug 31, 2023
Journal: International Journal of Innovative Surgery
Publisher: MedDocs Publishers LLC
Online edition: http://meddocsonline.org/
Copyright: © Yonemura Y (2023). This Article is distributed under the terms of Creative Commons Attribution 4.0 International License

Keywords: Neoplasms; HIPEC; Mesothelioma; Well-differentiated papillary mesothelioma; Intraperitoneal chemotherapy.

Abstract

Well-Differentiated Papillary Mesothelioma (WDPM) is a relatively rare disease with an indolent nature. However, due to its rarity, treatment policies differ between hospitals. The presented case was diagnosed with well-differentiated papillary mesothelioma after a diagnostic laparoscopy. She was treated with laparoscopic hyperthermic intraperitoneal chemotherapy followed by intraperitoneal chemotherapy and oral S-1 treatment. After three months, the patient underwent surgery with curative intent, with removal of all suspicious peritoneal sectors. Pathologic findings showed no residual tumor and normal mesothelial cells.
Introduction

Well-differentiated papillary mesothelioma (WDPM) is formally classified as a small subgroup of mesothelioma with benign behavior, subsequently renamed “well-differentiated papillary mesothelial tumor” (WDPMT) in the 2021 WHO classification [1]. Although most cases follow a benign course, some cases progress to malignant transformation [2]. Regarding treatment, there is no consensus about this relatively rare disease. Here, we report a case treated with Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (LHIPEC) and post-operative intraperitoneal chemotherapy with a complete pathologic response confirmed by definitive surgery.

Case Presentation

A 55-year-old woman with a history of diabetes and hypertension had lower abdominal pain since September 2022. She underwent laparoscopic examination that showed several peritoneal tumors (Figure 1,2). Pathologic examination confirmed the presence of well-differentiated papillary mesothelioma (Figure 3,4). She was transferred to our institution for further treatment. Imaging showed peritoneal thickening and ascites. Repeat laparoscopy in March 2023 showed several whitish nodules 2–5 mm in diameter on the peritoneal surface, with a total PCI (peritoneal cancer index) of 16. (Figure 1,2). We performed omental tumor biopsy and delivered LHIPEC with gemcitabine 1g + cisplatinum 50 mg at 43 degrees Celsius for 60 mins. After surgery, the patient was treated with intraperitoneal chemotherapy (docetaxel, cisplatin) combined with oral S-1 combination chemotherapy. Her final operation in June 2023 showed a markedly reduced peritoneal tumor load, with the PCI decreased to 3 and residual nodular lesions in the omentum and pelvis. We performed a combined pelvic and bilateral paracolic-gutter peritonectomy, total abdominal hysterectomy with a bilateral salpingo-oophorectomy, and low anterior resection to achieve complete resection. The final pathologic report showed no residual tumor and a normal, flat mesothelial cell lining (Figure 5). She was discharged uneventfully on postoperative day 16.
targets such as BAP1 and checks for mutations in TRAF7 and DMPM cases with DMPM may be initially diagnosed as WDPPM with aggressive biology may actually represent cases of DMPM challenging when based solely on morphological criteria. Thus cases that differentiation between DMPM and WDPPM may be chal

mesothelioma [1]. In the 2019 study by Deraco, they reported superficial sampling from a component of an invasive diffuse mesothelioma in situ. Accurate diagnosis of WDPMT requires mimic one another under the microscope: true WDPMT and diagnosis, we realized that there are two groups of disease that move diagnostic tissue instead of resecting all visible lesions. (Regarding the other two cases one with multiple lesions on the omentum underwent omentectomy and for the other, details are not mentioned). Due to the relative benign nature of the condition, it was thought reasonable to simply remove diagnostic tissue instead of resecting all visible lesions. However, WDPMT had been found to co-exist with other malignancies [40-45,50,51]. In addition, after the WHO redefined the diagnosis, we realized that there are two groups of disease that mimic one another under the microscope: true WDPMT and mesothelioma in situ. Accurate diagnosis of WDPMT requires examination of the entire lesion to exclude the possibility of superficial sampling from a component of an invasive diffuse mesothelioma [1]. In the 2019 study by Deraco, they reported that differentiation between DMPM and WDPPM may be challenging when based solely on morphological criteria. Thus cases with aggressive biology may actually represent cases of DMPM and cases with DMPM may be initially diagnosed as WDPPM and undertreated, when excisional biopsy or observation are used. They recommended further confirmation using molecular targets such as BAP1 and checks for mutations in TRAF7 and CDC42. In a 2022 review, Churg et al [52] also suggested routine checks that use immunostaining for BAP1, and if necessary MTAP or CDKN2A FISH on WDPMT. Several recent studies focus on genetic differences that might distinguish WDPM from malignant mesothelioma [53,54]. Because the prognosis of WDPM is very different from that of malignant mesothelioma, further treatment based on such genetic studies may be very valuable.

In the field of WDPMT treated by cytoreductive surgery with HIPEC, two large institutes (PSOGI and RENAPE) reported their results in 2019 [40,41]. The post-operative mortality was 2 of 111 cases. The post-operative major complication rate is around 20% (PSOGI: 24% and RENAPE reported grade 4 complications in 15%). Regarding recurrent cases, PSOGI had 8/45 recurrences (all within 5 years) and RENAPE had 4/56. In these two reports, the authors do not mention whether pathological findings after recurrence still showed WDPMT or malignant transformation to mesothelioma. The relatively high recurrence rate might be associated with selection bias due to more severe cases (median PCI 9 and 11 in each group) being referred to receive this type of surgery.

In 2013, Lee et al reported two cases with disseminated WDPMT treated with systemic chemotherapy (5-FU/CDDP x12 cycles and Pemetrexed/CDDP x 8 cycles), with complete responses. These two cases had no evidence of disease after 96 and 18 months, respectively [33]. In 2017, Bazire also reports a case of disseminated WDPMT treated with systemic chemotherapy (Pemetrexed/CDDP x 6 cycles) with a complete response. This patient had NED for 9 months [37]. In all three cases, a complete response was determined based on imaging and clinical findings only. Our patient had complete surgical removal of residual suspicious sites, confirming a complete response on pathological examination.

In 2010, Clarke et al reported a case with WDPM that had long-term follow-up for 24 years. This is the longest reported survival. However, she had three recurrences and underwent repeated surgeries. She also received adjuvant intraperitoneal and intravenous treatment and her course was complicated by anthracycline-induced heart failure, eventually managed with heart transplantation. She remains alive but after 24 years is not free of disease [25]. Acknowledging the concept proposed in 1990 [6], adjuvant treatment should be reserved for cases with evidence of progression. In 2013, Lee proposed the following therapeutic strategy: 1) for resectable disease, perform complete resection to minimize the risk of underdiagnosis; 2) for an irresectable condition, the patient who is asymptomatic with localized tumor extent can simply be followed up closely; 3) an irresectable condition with extensive disease or symptoms can be treated with chemotherapy. Here we suggest that local treatment using LHIPEC together with intraperitoneal chemotherapy and oral S-1 treatment might be a safe and effective treatment with a demonstrable pathologic response. Since WDPM comprises a thin lining of mesothelial cells, it is reasonable to treat the peritoneal surface. Applying a chemotherapeutic agent to the peritoneal surface allows easier penetration than occurs with a traditional intravenous route [55]. Although most chemotherapeutic drugs act on a specific part of the cell cycle, with the aid of heat above 43 Celsius, most cancer cells will be destroyed [56]. Combining the two mechanisms, hyperthermic intraperitoneal chemotherapy is advantageous in treating such diseases.

Discussion

In 1981, Foyle A et al. reported the first 25 female cases of this peritoneal tumor. Eight cases had WDPM with indolent behavior [3]. Subsequently there have been scattered cases reports with varying treatment policies (Table 1). A total of 306 cases were identified with an average age at diagnosis of 48 years. There is female predominance with a male/female ratio of 71/231 (four cases unknown). Most tumors were found incidentally during surgery for another reason, but other symptoms included pain and ascites causing abdominal distension. Before 1990, patients may have been treated with radiotherapy after surgery. However, after Daya reported two cases of post-operative radiation therapy with concerning complications (one died two years later from radiation enteritis; one died within 6 weeks of surgery and radiotherapy), radiotherapy has no longer been used for this disease. In their report, the authors suggested adjuvant therapy be used only when there is clear evidence of progression [6]. Most cases were treated with surgery alone (complete or incomplete resection) with acceptable complications and outcomes. Malignant transformation has however been reported. Among the 306 cases, five were reported to undergo malignant transformation at intervals of 1.2, 2.7 and 15 years. [5-39] All cases were diffusely distributed initially and three underwent biopsy alone (with non-curative intent) at initial surgery. (Regarding the other two cases one with multiple lesions on the omentum underwent omentectomy and for the other, details are not mentioned). Due to the relative benign nature of the condition, it was thought reasonable to simply remove diagnostic tissue instead of resecting all visible lesions. However, WDPMT had been found to co-exist with other malignancies [40-45,50,51]. In addition, after the WHO redefined the diagnosis, we realized that there are two groups of disease that mimic one another under the microscope: true WDPMT and mesothelioma in situ. Accurate diagnosis of WDPMT requires examination of the entire lesion to exclude the possibility of superficial sampling from a component of an invasive diffuse mesothelioma [1]. In the 2019 study by Deraco, they reported that differentiation between DMPM and WDPPM may be challenging when based solely on morphological criteria. Thus cases with aggressive biology may actually represent cases of DMPM and cases with DMPM may be initially diagnosed as WDPPM and undertreated, when excisional biopsy or observation are used. They recommended further confirmation using molecular targets such as BAP1 and checks for mutations in TRAF7 and CDC42.

In a 2022 review, Churg et al [52] also suggested routine checks that use immunostaining for BAP1, and if necessary MTAP or CDKN2A FISH on WDPMT. Several recent studies focus on genetic differences that might distinguish WDPM from malignant mesothelioma [53,54]. Because the prognosis of WDPM is very different from that of malignant mesothelioma, further treatment based on such genetic studies may be very valuable.

In the field of WDPMT treated by cytoreductive surgery with HIPEC, two large institutes (PSOGI and RENAPE) reported their results in 2019 [40,41]. The post-operative mortality was 2 of 111 cases. The post-operative major complication rate is around 20% (PSOGI: 24% and RENAPE reported grade 4 complications in 15%). Regarding recurrent cases, PSOGI had 8/45 recurrences (all within 5 years) and RENAPE had 4/56. In these two reports, the authors do not mention whether pathological findings after recurrence still showed WDPMT or malignant transformation to mesothelioma. The relatively high recurrence rate might be associated with selection bias due to more severe cases (median PCI 9 and 11 in each group) being referred to receive this type of surgery.

In 2013, Lee et al reported two cases with disseminated WDPMT treated with systemic chemotherapy (5-FU/CDDP x12 cycles and Pemetrexed/CDDP x 8 cycles), with complete responses. These two cases had no evidence of disease after 96 and 18 months, respectively [33]. In 2017, Bazire also reported a case of disseminated WDPMT treated with systemic chemotherapy (Pemetrexed/CDDP x 6 cycles) with a complete response. This patient had NED for 9 months [37]. In all three cases, a complete response was determined based on imaging and clinical findings only. Our patient had complete surgical removal of residual suspicious sites, confirming a complete response on pathological examination.

In 2010, Clarke et al reported a case with WDPM that had long-term follow-up for 24 years. This is the longest reported survival. However, she had three recurrences and underwent repeated surgeries. She also received adjuvant intraperitoneal and intravenous treatment and her course was complicated by anthracycline-induced heart failure, eventually managed with heart transplantation. She remains alive but after 24 years is not free of disease [25]. Acknowledging the concept proposed in 1990 [6], adjuvant treatment should be reserved for cases with evidence of progression. In 2013, Lee proposed the following therapeutic strategy: 1) for resectable disease, perform complete resection to minimize the risk of underdiagnosis; 2) for an irresectable condition, the patient who is asymptomatic with localized tumor extent can simply be followed up closely; 3) an irresectable condition with extensive disease or symptoms can be treated with chemotherapy. Here we suggest that local treatment using LHIPEC together with intraperitoneal chemotherapy and oral S-1 treatment might be a safe and effective treatment with a demonstrable pathologic response. Since WDPM comprises a thin lining of mesothelial cells, it is reasonable to treat the peritoneal surface. Applying a chemotherapeutic agent to the peritoneal surface allows easier penetration than occurs with a traditional intravenous route [55]. Although most chemotherapeutic drugs act on a specific part of the cell cycle, with the aid of heat above 43 Celsius, most cancer cells will be destroyed [56]. Combining the two mechanisms, hyperthermic intraperitoneal chemotherapy is advantageous in treating such diseases.
<table>
<thead>
<tr>
<th>First author</th>
<th>Year</th>
<th>Age (median)</th>
<th>M/F</th>
<th>No. of patient</th>
<th>Symptom</th>
<th>Site/Severity</th>
<th>Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Burrig [5]</td>
<td>1990</td>
<td>52</td>
<td>2/0</td>
<td>2</td>
<td>Incidental 2</td>
<td>both multiple, diffuse</td>
<td>biopsy only</td>
<td>one pt with malignant mesothelioma transformation after two yrs</td>
</tr>
<tr>
<td>Daya [6]</td>
<td>1990</td>
<td>40</td>
<td>4/18</td>
<td>22</td>
<td>Incidental 6; Pain 5; Mass 3; Ascites 3; Others 5</td>
<td>mainly omentum, pelvis, ovary</td>
<td>Nil: 11 Operation:9 C/T:4 R/T:5</td>
<td>two patients received R/T and died (one radiation enteritis; one within 6 weeks of surgery); in no treatment group 8/11NED for 11-14yrs</td>
</tr>
<tr>
<td>Lovell [7]</td>
<td>1990</td>
<td>11</td>
<td>0/1</td>
<td>1</td>
<td>Pain 1</td>
<td>diffuse</td>
<td>C/T+ surgery+GnRH agonist</td>
<td>AWD &gt; 9 months</td>
</tr>
<tr>
<td>Mangal [8]</td>
<td>1995</td>
<td>35</td>
<td>0/1</td>
<td>1</td>
<td>Pain 1</td>
<td>omentum, pelvis,</td>
<td>excision only</td>
<td>NED for 1 yr</td>
</tr>
<tr>
<td>Hoekman [9]</td>
<td>1996</td>
<td>36</td>
<td>0/3</td>
<td>3</td>
<td>Incidental 3</td>
<td>omentum, pelvis, diaphragm</td>
<td>tumor excision only</td>
<td>all NED for 7/6/1 yrs</td>
</tr>
<tr>
<td>Shukunami [10]</td>
<td>2000</td>
<td>56</td>
<td>0/1</td>
<td>1</td>
<td>Incidental 1</td>
<td>Diffused (omentum, pelvis)</td>
<td>tumor excision, IV/IP/p carboplatin</td>
<td>C/T effective to reduce ascites and pleural effusion; NED for 4 yr</td>
</tr>
<tr>
<td>Kim [11]</td>
<td>2001</td>
<td>60</td>
<td>0/1</td>
<td>1</td>
<td>Ascites 1</td>
<td>omentum</td>
<td>excision only</td>
<td>malignant mesothelioma at trocar site, ascites at 2 year interval</td>
</tr>
<tr>
<td>Butnor [12]</td>
<td>2001</td>
<td>44</td>
<td>5/1</td>
<td>6</td>
<td>Pain 3; Ascites 2</td>
<td>NR</td>
<td>chemo:3, Nil:1, unknown:2</td>
<td>1NED for 3yrs; 1 DOD 3yrs; 2AWD for 5/15 yrs</td>
</tr>
<tr>
<td>Porpora [13]</td>
<td>2002</td>
<td>46</td>
<td>0/1</td>
<td>1</td>
<td>Incidental 1</td>
<td>right uterosacral ligament</td>
<td>tumor excision only</td>
<td>NED for 3 yrs</td>
</tr>
<tr>
<td>Assaf N [14]</td>
<td>2002</td>
<td>55</td>
<td>1/0</td>
<td>1</td>
<td>Ascites 1</td>
<td>multiple</td>
<td>debulking surgery</td>
<td>NED for 2 yrs</td>
</tr>
<tr>
<td>Haba [15]</td>
<td>2003</td>
<td>48</td>
<td>0/1</td>
<td>1</td>
<td>Incidental 1</td>
<td>pelvis only</td>
<td>tumor excision</td>
<td>NR</td>
</tr>
<tr>
<td>Meister [16]</td>
<td>2003</td>
<td>45</td>
<td>1/0</td>
<td>1</td>
<td>Ascites 1</td>
<td>parietal peritoneum, omentum</td>
<td>tumor biopsy only</td>
<td>NR</td>
</tr>
<tr>
<td>Hoekstra [17]</td>
<td>2005</td>
<td>74</td>
<td>0/1</td>
<td>1</td>
<td>Incidental 1</td>
<td>multifocal</td>
<td>biopsy only</td>
<td>NED 12 mo</td>
</tr>
<tr>
<td>Gong [18]</td>
<td>2005</td>
<td>64</td>
<td>0/1</td>
<td>1</td>
<td>Incidental 1</td>
<td>liver surface, single</td>
<td>tumor excision only</td>
<td>NR</td>
</tr>
<tr>
<td>Lanneau [19]</td>
<td>2005</td>
<td>21</td>
<td>0/1</td>
<td>1</td>
<td>Incidental 1</td>
<td>posterior uterine fundus, single</td>
<td>tumor excision only</td>
<td>NR</td>
</tr>
<tr>
<td>Baratti [20]</td>
<td>2007</td>
<td>34.5</td>
<td>0/8</td>
<td>8</td>
<td>Incidental 4; Pain 2; Infertility 2</td>
<td>PCI:4+23</td>
<td>CRS+HIPEC</td>
<td>7 NED for 6-66 mo, 1DOD 13 mo (coexisting with biphasic mesothelioma)</td>
</tr>
<tr>
<td>Guo [21]</td>
<td>2007</td>
<td>41</td>
<td>0/1</td>
<td>1</td>
<td>Pain 1</td>
<td>diffused</td>
<td>biopsy only</td>
<td>alive &gt; 18 mo</td>
</tr>
<tr>
<td>Ikeda [22]</td>
<td>2008</td>
<td>73</td>
<td>0/1</td>
<td>1</td>
<td>Incidental 1</td>
<td>diffused</td>
<td>biopsy, C/T with paclitaxel</td>
<td>alive &gt; 11 mo</td>
</tr>
<tr>
<td>Collin [23]</td>
<td>2009</td>
<td>46</td>
<td>0/1</td>
<td>1</td>
<td>Incidental 1</td>
<td>NR</td>
<td>surgery only</td>
<td>NED &gt; 9 mo</td>
</tr>
<tr>
<td>Wheeler [24]</td>
<td>2009</td>
<td>63</td>
<td>1/0</td>
<td>1</td>
<td>Incidental 1</td>
<td>anterior abdominal wall localized</td>
<td>surgery only</td>
<td>Alive &gt; 13 mo</td>
</tr>
<tr>
<td>Clarke [25]</td>
<td>2010</td>
<td>36</td>
<td>0/1</td>
<td>1</td>
<td>Pain 1</td>
<td>diffused</td>
<td>surgery x3, IP and IV C/T</td>
<td>AWD &gt; 24 yrs; C/T related heart failure s/p heart transplant</td>
</tr>
<tr>
<td>Hatano [26]</td>
<td>2011</td>
<td>45</td>
<td>1/0</td>
<td>1</td>
<td>Incidental 1</td>
<td>Single, from omentum</td>
<td>tumor excision only</td>
<td>NED for 3 yrs</td>
</tr>
<tr>
<td>Malpica [27]</td>
<td>2012</td>
<td>47</td>
<td>0/26</td>
<td>26</td>
<td>Incidental 24; Pain 2</td>
<td>single:13 multiple:13</td>
<td>excision only</td>
<td>22 NED for 5-144mo; one recurrence at 46.5 mo; 3DCC</td>
</tr>
<tr>
<td>Nemoto [28]</td>
<td>2012</td>
<td>73</td>
<td>0/1</td>
<td>1</td>
<td>Ascites 1</td>
<td>multiple</td>
<td>5-1-&gt;excision--&gt;C/T TXL+irinotecan/CDDP</td>
<td>progression with malignant transformation 1 year, DOD at 54 mo</td>
</tr>
<tr>
<td>Anirudhan [29]</td>
<td>2012</td>
<td>48</td>
<td>1/0</td>
<td>1</td>
<td>Incidental 1</td>
<td>single from hernia sac</td>
<td>tumor excision only</td>
<td>NR</td>
</tr>
<tr>
<td>Chen [30]</td>
<td>2013*</td>
<td>37</td>
<td>4/14</td>
<td>18</td>
<td>Most incidental</td>
<td>single: 8 multiple:10</td>
<td>tumor excision</td>
<td>8 NED for 5-102mo; 7 NETP for 17-136mo; 1 DOD (coexisting cervical cancer)</td>
</tr>
<tr>
<td>Ribeiro [31]</td>
<td>2013</td>
<td>56 &amp; 44</td>
<td>0/2</td>
<td>2</td>
<td>Pain 1</td>
<td>multiple:2</td>
<td>tumor biopsy+ C/T CDDP+pemetrexed :1; C/T CDDP+pemetrexed :1</td>
<td>NETP:1, DOD:1 at 12 yrs</td>
</tr>
<tr>
<td>Washimi [32]</td>
<td>2013</td>
<td>58</td>
<td>0/1</td>
<td>1</td>
<td>Incidental 1</td>
<td>multiple</td>
<td>tumor excision only</td>
<td>malignant transformation to mesothelioma at 7 yrs</td>
</tr>
<tr>
<td>Lee [33]</td>
<td>2013</td>
<td>53</td>
<td>6/9</td>
<td>15</td>
<td>Incidental 11; Pain 2; Ascites 2</td>
<td>single:8; multiple:7 (local- ized 3 disseminated 4)</td>
<td>single-&gt;4/8 excision only, 4/8 +C/T; Multiple-&gt;2/7 ex only, 5/7+C/T</td>
<td>single: NED in 6 for 12~146 mo; DOC in 2; multiple: NED in 2 AWD in 4, DOD in 1 (110 mo)</td>
</tr>
<tr>
<td>Val-Bernal [34]</td>
<td>2014</td>
<td>66</td>
<td>1/0</td>
<td>1</td>
<td>Incidental 1</td>
<td>NR</td>
<td>excision of hernia sac</td>
<td>NED for 103mo</td>
</tr>
<tr>
<td>Nasit [35]</td>
<td>2014</td>
<td>28</td>
<td>0/1</td>
<td>1</td>
<td>Pain 1</td>
<td>diffused</td>
<td>complete resection</td>
<td>recurrence at 9mo -&gt;C/T with CDDP+doxorubicin</td>
</tr>
<tr>
<td>Jakobsen [36]</td>
<td>2016</td>
<td>63</td>
<td>1/0</td>
<td>1</td>
<td>Incidental 1</td>
<td>multiple, localized</td>
<td>tumor excision</td>
<td>NR</td>
</tr>
<tr>
<td>Bazine [37]</td>
<td>2017</td>
<td>36</td>
<td>1/0</td>
<td>1</td>
<td>Pain 1</td>
<td>diffuse</td>
<td>biopsy then C/T with CDDP+pemetrexed x6</td>
<td>NED for 9mo</td>
</tr>
<tr>
<td>Saha [38]</td>
<td>2018</td>
<td>28</td>
<td>0/1</td>
<td>1</td>
<td>Pain 1</td>
<td>single</td>
<td>resection</td>
<td>NED for 9 mo</td>
</tr>
</tbody>
</table>
## Conclusion

Here we reported a case of WDPM treated with LHIPEC and the post-operative combination of intraperitoneal and oral systemic chemotherapy. The patient then underwent definitive surgery with a maximal resection of peritoneum. We were surprised that the final pathologic report showed no residual tumor. This is the first report to describe an excellent response to the combination of LHIPEC and a two-pronged post-operative treatment approach. LHIPEC combined minimal operative risk with further treatment comprising bi-weekly intraperitoneal chemotherapy combined with oral 5-Fluorouracil. This is an alternative, simple and safe approach to treating this condition.

## Reference


54. Shrestha R, Nabavi N, Volik S, et al. Well-Differentiated Papillary Mesothelioma of the Peritoneum Is Genetically Distinct from...
